New drug duo aims to tackle tough leukemia

NCT ID NCT06382168

Recruiting now Disease control Sponsor: Delta-Fly Pharma, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests a combination of two drugs, DFP-10917 and venetoclax, in 39 adults with acute myeloid leukemia that has relapsed or not responded to prior treatments. DFP-10917 is given as a continuous 14-day IV infusion, while venetoclax is taken orally for 10-14 days each cycle. The goal is to find a safe dose and see if the combination can help control the leukemia.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DFP-10917 and venetoclax
What this could lead to: If successful, this combination could offer a new treatment option for people with acute myeloid leukemia that has come back or not responded to prior therapy.
What could go wrong: This is an early-phase trial with only 39 participants, so results may not apply broadly. The drugs may cause serious side effects, and the combination might not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, MYELOID, ACUTE

Contacts and locations

Locations

Atrium Health Wake Forest Baptist Comprehensive Cancer Center
RECRUITING

Winston-Salem, North Carolina, 27157, United States
UCI Chao Family Comprehensive Cancer Center
RECRUITING

Orange, California, 92868, United States
University of Vermont Cancer Center
RECRUITING

Burlington, Vermont, 05401, United States
University of Virginia Cancer Center
RECRUITING

Charlottesville, Virginia, 22911, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.